ALKS
Alkermes plc.
Latest Form 4:Sale$373KbyNichols Christian Todd (SVP, Chief Commercial Officer) · filed Aug 17, 2026
Alkermes plc. (ALKS) has 55 SEC Form 4 filings (116 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 17, 2026.
The most active filer is EVP R&D, Chief Medical Officer Hopkinson Craig C. with 13 filings. Insiders have net sold $6.5M over the trailing 6 months.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Blair Jackson
- Employees:2,050
- HQ:Dublin, DU, IE
- IPO:1991-07-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$10.0M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$8.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Nichols Christian ToddFirst in 6 months | SVP, Chief Commercial Officer | Sale | 7,576 | $373K | Aug 17 | SEC ↗ |
snyderman nancy lynn MDFirst filing | Director | Sale | 44,472 | $2.2M | Aug 3 | SEC ↗ |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $437K | Aug 3 | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $99K | Aug 3 | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $110K | Jul 6 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $464K | Jul 1 | SEC ↗ | |
Wright Christopher IFirst filing | Director | Sale | 2,000 | $90K | Jun 13 | SEC ↗ |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $88K | Jun 4 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $375K | Jun 1 | SEC ↗ | |
| VP, Finance (Interim PAO) | Sale | 16,217 | $687K | May 29 | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $68K | May 5 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $301K | May 2 | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $70K | Apr 6 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $320K | Apr 1 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $267K | Mar 4 | SEC ↗ | |
Gaffin David JosephFirst filing | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $60K | Mar 4 | SEC ↗ |
Gaffin David JosephFirst filing | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $61K | Mar 4 | SEC ↗ |
Nichols Christian ToddFirst filing | SVP, Chief Commercial Officer | Sale | 6,000 | $180K | Mar 4 | SEC ↗ |
Parisi Samuel JosephFirst filing | VP, Finance (Interim PAO) | Sale | 6,890 | $202K | Mar 4 | SEC ↗ |
Cooke ShaneFirst filing | Director | Sale | 61,200 | $2.1M | Feb 2 | SEC ↗ |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $305K | Feb 2 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 5,000 | $150K | Jan 8 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 4,000 | $112K | Jan 2 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 3,748 | $112K | Dec 5 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 4,000 | $117K | Dec 1 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $273K | Nov 3 | SEC ↗ | |
Hopkinson Craig C.First filing | EVP R&D, Chief Medical Officer | Sale | 9,000 | $284K | Oct 15 | SEC ↗ |
Related companies
Alkermes plc. is in the Healthcare sector.